A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Exclusion Criteria

• •Women who are pregnant, breastfeeding
• •History of deep vein thrombosis or pulmonary embolism
• •Active bleeding or at high risk of bleeding
• •Metastatic brain cancer
• •Familial bleeding diathesis
• •Serious hemorrhage requiring hospitalization, transfusion, or surgical intervention within 4 weeks of study entry
• •Expected survival \<6 months or an Eastern Cooperative Oncology Group performance status ≥3.
• •Candidates for bone marrow transplantation within the 12-week treatment period or 30-day follow-up period
• •Uncontrolled hypertension (systolic blood pressure \>200 mm Hg and/or diastolic blood pressure \>110 mm Hg
• •Coagulopathy (international normalized ratio \>1.5 or platelet count \<100\*10\^9/L) if not yet receiving chemotherapy or \<50\*10\^9/L if receiving chemotherapy). Platelet count must have been \>100\*10\^9/L before starting study medication
• •One or more of the following: alanine aminotransferase \>3 times the upper limit of normal (ULN), total bilirubin \>2\*ULN, or calculated creatinine clearance \<30 mL/min.